Comparison of high resolution cytogenetics, fluorescence in situ hybridisation, and DNA studies to validate the diagnosis of Prader-Willi and Angelman’s syndromes

A Smith, M Prasad, Z-M Deng, L Robson, T Woodage, R J Trent

Abstract
Eighty seven referrals with Prader-Willi syndrome and 49 with Angelman’s syndrome were studied. High resolution cytogenetics was performed on all probands. Molecular studies, performed on the proband and both parents in each case, utilised multiple probes from within and distal to the 15(q11-13) region in order to establish the presence of DNA deletion or uniparental disomy. In addition, FISH, with probes at D15S811 and GABRB3 from the Prader-Willi syndrome/Angelman’s syndrome region, was performed on a subset of 25 of these patients.

In the referral group with Prader-Willi syndrome, 62 patients had a normal karyotype and 25 were deleted on high resolution cytogenetics. Twenty nine were found to be deleted with DNA technologies. In the Angelman’s syndrome group, 37 had a normal karyotype and 12 were deleted on high resolution cytogenetics while 26 were deleted on molecular studies. The diagnosis was reassessed in 35 referrals with Prader-Willi syndrome and 11 with Angelman’s syndrome following a non-deleted, non-disomic result. Of individuals who were neither deleted nor disomic on DNA studies, a false positive rate of 11-4% (4/35) for Prader-Willi syndrome and 16-7% (2/12) for Angelman’s syndrome was found for a cytogenetically detected deletion. The false negative rate for deletion detected on high resolution cytogenetics was 19-5% (12/62) for Prader-Willi syndrome and 35% (13/37) for Angelman’s syndrome. Thus high resolution cytogenetics was shown to be unreliable for deletion detection and should not be used alone to diagnose either syndrome. There were no discrepancies with FISH in 25 cases when FISH was compared with the DNA results, indicating that FISH can be used reliably for deletion detection in both syndromes.

Arch Dis Child 1995; 72: 397-402

Keywords: deletion, uniparental disomy, abnormal phenotype.

The Prader-Willi syndrome was first described in 1956 in nine patients who had diminished fetal activity, severe infantile hypotonia, feeding problems in infancy, hypogonadism and hypogonitalism, short stature, small hands and feet, delayed psychomotor development, characteristic facial appearance, mild mental retardation, in satiable hunger leading to the onset of gross obesity during early childhood, behaviour problems, and tendency to develop diabetes in adolescence. These features can be quite variable between individual patients, and a diagnostic scoring system has been devised to aid diagnosis. The scoring system gives points to features present from birth to 3 years of age and for features after 3 years of age, when it is generally considered that the diagnosis is more straightforward. Angelman’s syndrome was first described in 1965 on the basis of features in three young children. These features included severe mental retardation, epilepsy, tongue thrusting and drooling, an ataxic gait, and microcephaly. The facial features of Angelman’s syndrome are subtle and non-specific and atypical cases have been described. A simple reliable diagnostic test would be extremely valuable for both syndromes in early childhood when the diagnosis is first suspected.

The association between an interstitial deletion of chromosome 15 and Prader-Willi syndrome was shown in 1981, and a similar interstitial deletion of the same region of chromosome 15 was shown in Angelman’s syndrome in 1987. Cytogenetically detected interstitial deletions provided the first laboratory diagnostic test for these syndromes and considerable reliance came to be placed on the results of high resolution cytogenetics. Deletions of the proximal part of chromosome 15q were reported in about 60% of patients with Prader-Willi syndrome and a similar proportion of those with Angelman’s syndrome with high resolution cytogenetic techniques. Approximately one third were apparently normal cytogenetically, and 3-5% showed other chromosomal anomalies involving chromosome 15.

The development of molecular probes for the Prader-Willi syndrome and Angelman’s syndrome region of 15(q11-13) enabled alternate or complementary means for the detection of deletions in patients. Molecular studies not only demonstrated deletion, but also the parent of origin of the deletion. The deleted 15(q11-13) chromosome in patients with Prader-Willi syndrome always originates from the father while in Angelman’s syndrome patients the deletion originates...
Patients and methods

Patients

Patients with a diagnosis or suspicion of Prader-Willi syndrome or Angelman’s syndrome were referred by clinicians throughout Australia and New Zealand or the diagnosis was made by one of us (AS) in consultation with the referring doctor. The criteria used to establish the diagnosis of Prader-Willi syndrome were neonatal hypotonia, hyperphagia in early childhood with obesity, mild mental retardation, short stature, the characteristic facies seen in Prader-Willi syndrome, and hypogonadism. The clinical evaluation of many of these patients has been previously described (patients 1–30); individual patients (25–26). Subsequent patients were classified in the same way using standard diagnostic criteria.

Non-deleted, non-disomic cases comprise 25–30% of Angelman’s syndrome and are a particular concern because recurrence occurs commonly within this group. When reports of the DNA studies became available, some discrepancies were noted between cytogenetic results and the DNA findings.

The technique of fluorescence in situ hybridisation (FISH) is a relatively new molecular cytogenetic technique in which specific DNA probes are applied directly to chromosome spreads on slides. These slides can be used for routine analysis first with high resolution G banding, or FISH can be applied to freshly prepared preparations. The technique is simpler than standard DNA studies and does not require specimens from the parents of the patient for deletion detection. FISH has proved to be highly accurate with many probes. FISH utilising probes from the Prader-Willi syndrome/Angelman’s syndrome chromosome region has not been formally compared with DNA studies in these patients.

In the present study, 87 patients with the referral diagnosis of Prader-Willi syndrome and 49 patients referred with the diagnosis of Angelman’s syndrome were examined with high resolution cytogenetics and detailed molecular analysis. Several patients whose diagnosis did not clearly fit either syndrome but who displayed some similar features were also included. Examination of such individuals is important for determining the range of clinical features that could potentially be associated with deletion or uniparental disomy of chromosome 15. In addition a cohort of 25 of these patients (seven with Prader-Willi syndrome and 18 with Angelman’s syndrome) was examined by FISH. From the comparison of these findings, a strategy for the laboratory diagnosis of Prader-Willi syndrome and Angelman’s syndrome can be proposed.

CYTOGENETICS

Cytogenetic analysis was performed on all probands either in the Children’s Hospital, Camperdown laboratory or in the state or New Zealand laboratory associated with the referring doctor. Peripheral blood lymphocytes were cultured using methods that increase the frequency of late prophase to early metaphase chromosomes. Karyotype analysis with GTG banding (G band chromosomes with GTG banding) was performed to search for a chromosome 15 microdeletion. Resolution varied from the 650 to 850 band stage but when difficulties of interpretation were encountered, the cytogenetic results were considered as non-deleted. The parents of probands were not routinely tested by cytogenetic techniques.

DNA ANALYSIS

Molecular studies were performed on the patients and both parents in each case. High molecular weight DNA was prepared from peripheral blood specimens according to standard methods. Polymorphism analysis was performed with restriction fragment length polymorphisms, variable number of tandem repeats, and the polymerase chain reaction based simple sequence repeats with probes for loci from within the Prader-Willi syndrome/Angelman’s syndrome chromosome region (D15S18, D15S9, D15S11, D15S13, D15S10, D15S113, D15S97, GABRB3, D15S12) and outside the region distally on
Validation of PWS/AS

chromosome 15 (D15S24, ACTC, THBS1, D15S87, D15S86). DNA patterns at each polymorphic locus were recorded according to the bands seen on the autoradiographs or polyacrylamide gels. Detailed methods and the probe–enzyme combinations used have been previously described.22–24 Usually five polymorphisms per patient were sufficiently informative to establish whether a deletion or uniparental disomy was present, the parent of origin, or if the patient was non-deleted, non-disomic.

FISH

The probes used were from the 15(q11-13) region and comprised DNA specific for the loci D15S11 for Prader-Willi syndrome and GABRB3 for Angelman’s syndrome (Oncor). The probes are supplied as single stranded DNA labelled with digoxigenin. After hybridisation on to denatured chromosomal preparations19–26 detection was via immuno-cytochemical incubations with an antidigoxigenin mouse monoclonal antibody (Boehringer Mannheim) and a fluorescein conjugated sheep antimouse IgG antibody (Boehringer Mannheim). The preparation was counterstained with a combination of propidium iodide (Calbiochem) and 4',6-diamidino-2-phenylindole (Sigma). The probes available for FISH have been modified to provide ease of usage by the incorporation of a DNA marker (also digoxigenin labelled) on the long arm of chromosome 15 at q22 (fig 1). The distal marker acts as an internal control for successful hybridisation and aids in the quick assessment of a deletion (fig 2).

Results

The results of high resolution cytogenetics and DNA testing and their correlation are shown in table 1. Of the total 87 patients referred with Prader-Willi syndrome, 62 showed normal chromosomes and 25 showed a deletion on high resolution cytogenetics. The DNA findings showed overall that 29 patients had a deletion, 20 had uniparental disomy, and 36 were non-deleted, non-disomic. All patients with deletion and uniparental disomy had classical Prader-Willi syndrome. Clinical reassessment of the 38 non-deleted, non-disomic patients resulted in 35 being reclassified as atypical Prader-Willi syndrome or non-Prader-Willi syndrome. Re-evaluation of the remaining three patients (case numbers 28, 29, 30 in Woodage et al24) indicated that they had features supportive of a diagnosis of Prader-Willi syndrome and remain in the classification of classical Prader-Willi syndrome patients. The 29 deleted patients and the 20 patients with uniparental disomy all had...
Table 1 Correlation of high resolution cytogenetic findings with the DNA results for all referrals

<table>
<thead>
<tr>
<th>Cytogenetics</th>
<th>DNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal Deleted</td>
</tr>
<tr>
<td>Prader-Willi syndrome (n=87)</td>
<td>62 – 12 16 34</td>
</tr>
<tr>
<td>Angelman’s syndrome (n=49)</td>
<td>37 – 13 1 23</td>
</tr>
</tbody>
</table>

Indicates cases with discrepancy between high resolution cytogenetics and DNA results. There were no discrepancies between the FISH and DNA results.

Discussion

The results of this study show considerable discrepancy between high resolution cytogenetics and DNA findings. Using DNA as the diagnostic standard, we found for Prader-Willi syndrome and Angelman’s syndrome false positive rates of 12% and 17% and false negative rates of 20% and 35% respectively for deletion detection with high resolution cytogenetics. Overall, among the whole group of referrals with Prader-Willi syndrome, deletions were detected less frequently than expected, reflecting the finding that nearly half the patients were atypical. Among the classical Prader-Willi syndrome patients, there were many with uniparental disomy (38%) and high resolution cytogenetics cannot pick up this group. Thus it is clear that reliance cannot be placed upon the result of the high resolution cytogenetics test for the diagnosis of Prader-Willi syndrome or Angelman’s syndrome. Discrepant results and submicroscopic DNA deletions not detected on high resolution cytogenetics have been reported in both Prader-Willi syndrome and Angelman’s syndrome in smaller groups of patients.

Reasons for discrepancies between high resolution cytogenetics and DNA studies have been documented. False negative results are partly due to the greater resolution of DNA compared with cytogenetics. At the 1000 band stage of resolution, one cytogenetic band could contain five megabases of DNA, so that a normal high resolution cytogenetics result does not exclude a smaller DNA deletion. False positive results can be accounted for in part by common polymorphisms of the chromosome 15 pericentromeric region, which include duplications and deletions. Replication asynchrony between homologues in the proximal long arm region has been demonstrated and can result in one chromosome 15 homologue appearing to be shorter than the other. It could be expected that the success of high resolution cytogenetics would vary.
Validation of PWS/AS

Figure 3  Flow diagram with suggested protocol for the investigation of Prader-Willi syndrome (PWS) and Angelman’s syndrome (AS).

between laboratories and in the same laboratory over time. A further factor in clinical work is the subjective nature of the assessment, influenced by the conviction and communication of the referring doctor. High resolution cytogenetics is also time consuming and labour intensive.

The emergence of FISH as an accurate molecular cytogenetic technique when validated against DNA studies suggested that FISH could replace high resolution cytogenetics for deletion detection in the microdeletion syndromes, should suitable probes become available. The advent of probes specific for the Prader-Willi syndrome and Angelman’s syndrome regions has now opened this field for FISH work. In our study, the correlation of the FISH and DNA results was 100% and the cases discrepant on high resolution cytogenetics could be resolved with FISH. In another study comparing FISH and high resolution cytogenetics, FISH was considered to be superior to high resolution cytogenetics, but the data presented in that report were not compared with DNA results such as has been done here. Our data establish the validity of the use of FISH as an accurate technique for deletion detection in both Prader-Willi syndrome and Angelman’s syndrome. Furthermore FISH is a fairly rapidly performed molecular technique and signal visualisation is not difficult with the incorporation of the 15q22 marker with the probe. The probes themselves are relatively expensive, but ultimately FISH may be more cost effective than high resolution cytogenetics in deletion detection due to the increased accuracy and time savings compared with the more laborious high resolution cytogenetics analysis.

Due to the high accuracy of FISH in deletion detection in Prader-Willi syndrome and Angelman’s syndrome, we suggest that this technique should replace high resolution cytogenetics in the diagnosis of these patients. Routine cytogenetics with GTG banding must be performed on all suspected patients due to the possibility of structural rearrangements involving chromosome 15 which occur in about 5% of Prader-Willi syndrome and Angelman’s syndrome individuals. For this reason, FISH cannot be the sole technique without cytogenetics, as has been suggested.

A sensible strategy for the investigation of suspected Prader-Willi syndrome/Angelman’s syndrome patients is outlined in fig 3. Routine cytogenetics is performed first and then FISH on the same culture or slides as was used for the initial routine cytogenetics. Our procedure now is to make an extra slide for FISH at the time of the cytogenetic harvest. This protocol will diagnose the majority of both Prader-Willi syndrome and Angelman’s syndrome patients as approximately 70% have a large DNA deletion. FISH accurately reflects the DNA deletion so that when a deletion is detected, no further DNA testing needs to be performed. In those cases in which a deletion is not detected by FISH, clinical reassessment is valuable to suggest if any further testing is warranted. Some cases may be withdrawn at this stage. If DNA testing is to be undertaken, this may follow standard polymorphic marker analysis, requiring specimens from the parents. For classical Prader-Willi syndrome patients, uniparental disomy will be shown to be the mechanism in the great majority of the non-deleted patients, and verification of uniparental disomy can be sought by DNA testing with terminal 15q markers only. Alternatively, DNA testing could be performed by the methylation technique which relies on methylation sensitive restriction enzymes differentially cutting maternal and paternal DNA. The methylation patterns obtained can diagnose Prader-Willi syndrome and Angelman’s syndrome accurately but cannot distinguish between the mechanism of deletion or uniparental disomy. Methylation testing is more rapid and less expensive than full polymorphic studies and does not require parental blood samples. Several methylation sites are present in the 15q11-13 region, including PW71 which has proved to be useful for clinical diagnosis and can act as a break down when parent samples are not available. Among patients with Angelman’s syndrome approximately one third remain unresolved with the current DNA probes available. It is important to establish the mechanism because the recurrence risks are very low for uniparental disomy but up to 50% if the patient is non-deleted, non-disomic. These patients should be kept under review for retesting as the Angelman’s syndrome gene is defined.

While DNA testing can be time consuming and expensive, FISH has reduced by two thirds the number of cases requiring full DNA work up and is thus additionally cost effective. The selective use of DNA studies proposed with this strategy will keep the total cost of investigation to a minimum but also identify those patients where further detailed DNA studies are warranted.

We thank Professor D Sillence, Head, Department of Genetics, Children’s Hospital, Camperdown, for his support. The DNA work was performed under a grant from the National Health and Medical Research Council, Australia.
Gingrich & Zackowski
16

Williams & Butler
13

Magenis, RE, Brown
6

Holm, VA & Cassidy, SB,
2
Block, TD & Holm, VA
1


Gingrich & Shadravan F, Lowry SR. A fluorescence in situ map of human chromosome 21 consisting of 20 genetic and physical markers on the chromosome: localization of 137 additional YAC and cosmid clones with respect to this map. Genomics 1993; 17: 98-105.


Smith A, Noel M. A girl with the Prader-Willi syndrome and Robertsonian translocation 45,XX,t(14;15)(p11q11) which was present in three normal family members. Hum Genet 1983; 65: 813-6.


